Advanced Cholangiocarcinoma Clinical Trial
Official title:
Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
Primary Objectives: • To assess the antitumor activity of the treatment combinations based on objective response rate (ORR) Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. This assessment will be confirmed in the next scheduled scan. Secondary Objectives: 1. To determine the safety and recommended phase 2 dose (RP2D) of the triple combination of pemigatinib with bevacizumab and atezolizumab in participants with FGFR-altered metastatic CCA. 2. To evaluate the duration of response in participants with best overall response of complete response (CR) or partial response (PR). 3. To evaluate PFS defined as the time from the start of study treatment to disease progression or death, whichever occurs first. 4. To evaluate the duration of OS defined as the time from the start of study treatment to death from any cause. 5. To evaluate the clinical benefit rate defined as the proportion of participants with best overall response of CR, PR, or stable disease. 6. To evaluate safety and endpoints 2-5 with the doublet of pemigatinib with atezolizumab. Exploratory Objectives: • To examine the change of the immune microenvironment on treatment by the combination using a validated immune biomarker panel and end-of-treatment genomic markers using cfDNA to study resistance to pemigatinib and response markers from trial medications. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05823311 -
Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma
|
Phase 3 | |
| Recruiting |
NCT06420349 -
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
|
Phase 1 | |
| Recruiting |
NCT05727176 -
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
|
Phase 2 | |
| Recruiting |
NCT05791448 -
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
|
Phase 1 | |
| Active, not recruiting |
NCT04093362 -
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
|
Phase 3 | |
| Recruiting |
NCT03996408 -
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02982720 -
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
|
Phase 2 | |
| Terminated |
NCT02150967 -
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
|
Phase 2 | |
| Recruiting |
NCT03982680 -
Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma
|
Phase 2 | |
| Recruiting |
NCT05532059 -
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma
|
Phase 2 | |
| Terminated |
NCT04088188 -
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
|
Phase 1 | |
| Completed |
NCT02989857 -
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
|
Phase 3 | |
| Recruiting |
NCT05805956 -
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
|
Phase 1/Phase 2 | |
| Terminated |
NCT03773302 -
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
|
Phase 3 | |
| Approved for marketing |
NCT04507503 -
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
|